To analyze rectal dose and changes in quality of life (QOL) measured with the Expanded Prostate and Cancer Index Composite (EPIC) bowel domain in patients being treated for prostate cancer with curative-intent proton beam therapy (PBT) within a large single-institution prospective registry.
Data was collected from 243 patients with localized prostate cancer treated with PBT from 2016 to 2018. The EPIC survey was administered at baseline, end-of-treatment, 3, 6, and 12 months, then annually. Dose-volume histogram (DVH) parameters for the rectum were computed, and rectal dose was analyzed using BED (α/β = 3), EQD2Gy, and total dose. Repeated measures mixed models were implemented to determine the effect of patient, clinical, and treatment factors (including DVH) on patient-reported bowel symptom burden (EPIC-Bowel).
Treatment overall resulted in changes in EPIC-Bowel scores (baseline score = 93.7), most notably at end-of-treatment (90.6) and 12 months (89.7). However, they returned to baseline at 36 months (92.9). On multivariate modeling, rectal BED D25 (Gy) ≥23% was significantly associated with decline in QOL scores measuring bother (p < 0.01; 4.06 points different).
Rectal doses, specifically BED D25 (Gy) ≥23%, are significantly associated with decline in bowel bother-related QOL in patients undergoing definitive radiotherapy for localized prostate cancer. This study demonstrates BED as an independent predictor of bowel QOL across dose fractionations of PBT.
Prostate cancer is the most common cancer in American men, with roughly 200,000 new cases and 30,000 deaths annually [
The EPIC survey measures health-related quality of life across a variety of disease-specific domains such as urinary, bowel, and sexual function [
Previous studies have demonstrated statistically and clinically significant changes in EPIC-Bowel scores for patients receiving PBT for prostate cancer [
The Institutional Review Board of Mayo Clinic Arizona approved the study and all patients provided written informed consent (No. 19-007866). This trial was registered with ClinicalTrials.gov (NCT01255748).
Adult males undergoing definitive radiotherapy for localized prostate cancer from January 1, 2016 to December 31, 2018 were originally assessed for eligibility. To be included, patients must have received proton RT with curative intent, and completed at least one pre-RT and one post-RT EPIC questionnaire. Patients with node-positive or metastatic disease were excluded. The final number of patients enrolled was 243.
Patients underwent computed tomography (CT) simulation with pelvic immobilization, a full bladder, and a rectal balloon. Carbon fiducial markers were placed prior to simulation. Some patients also had a rectal spacer placed between the prostate and rectum at the discretion of the treating physician. A treatment planning magnetic resonance imaging (MRI) was obtained and co-registered with CT images for target delineation. In patients who could not undergo MRI scans, treatments were planned using CT, positron emission tomography (PET), and bone scans. The clinical target volume (CTV) encompassed the entire prostate gland and proximal seminal vesicles. In cases of T3b disease, the entire seminal vesicles were included in CTV. An optimization target volume (OTV) was created from the CTV using a margin of 2–3 mm posteriorly and 3 mm elsewhere. Treatment was delivered with right and left lateral beams. The constructed OTV included an additional 5 mm in the beam direction distally and proximally due to range uncertainty. Usual proton beams were oriented laterally left and right. Image guidance with matching to carbon fiducial markers was performed to confirm daily set up.
For the purpose of this study, conventional fractionation denotes dose per fraction between 1.8 and 2 Gy (relative biological effectiveness [RBE]). Hypofractionation was defined as treatment regimens of more than 5 fractions with over 2 Gy (RBE) per fraction. Extreme hypofractionation (stereotactic body radiation therapy [SBRT]) was defined as treatments of 5 fractions or less, typically ≥6 Gy (RBE) per fraction. Spot scanning proton beam was used for all treatments.
Rectal dose-volume histogram (DVH) parameters collected from treatment plans were computed with Dx signifying dose (Gy) delivered to a percentage of rectal tissue volume. Vx denoted the percentage of rectum volume receiving at least a given dose (Gy). Assuming an alpha-beta ratio of 3, both the biologically effective dose (
Institutional guidelines for conventional fractionation, hypofractionation, and extreme fractionation were utilized when determining rectal dose constraints. For conventional fractionation: V65 (Gy) ≤50%; hypofractionation: V61 (Gy) ≤15%; and extreme hypofractionation: V33.5 (Gy) ≤15%. For the hypofractionation schemes, the higher dose constraints were approximately 10% greater than conventional fractionation protocols: BED of 98.5 Gy (65 Gy nominal) for conventional, 110 Gy (61 Gy nominal) for hypofractionation, and 108 Gy (33.5 Gy nominal) for extreme hypofractionation.
Toxicity was measured with the Common Terminology Criteria for Adverse Events (version 5.0).
The EPIC is a survey tool used to measure health-related QOL through assessment of urinary, bowel, sexual, and hormonal burden during treatment of prostate cancer [
Rectal dose was analyzed using BED (alpha/beta = 3), EQD2Gy, and total dose. Univariate analysis utilizing repeated measures mixed models was utilized to determine the “best” DVH parameter associated with differences in patient-reported QOL. An outcome-oriented approach (with alpha-adjustment to control for family-wise error) was used to determine the optimal dichotomization of the DVH parameter of interest with the largest association to changes in patient-reported QOL. Multivariate repeated measures mixed models with unstructured covariance matrices were implemented to determine the effect of patient, clinical, and treatment factors (including DVH) on patient-reported bowel symptom burden (EPIC-Bowel overall, function, and bother scores).
The present analysis includes 243 patients from January 1, 2016 to December 31, 2018, treated for prostate cancer in accordance with institutional protocols. Patient and tumor characteristics are displayed in
The median follow-up time was 20 months (range, 2.5 to 40 months). Dose fractionations are presented in
DVH parameters were determined by BED, EQD2Gy, and total dose. Each continuous parameter was tested for associations with significant decline in EPIC scores at intervals of 5% in volume and 5 Gy for dose. The univariately significant DVH parameters are displayed in
Globally, treatment had expected effects over EPIC-Bowel scores which returned to baseline over time, with a median baseline score (93.7), end-of-treatment (90.6), 3 months (92.1), 6 months (92.7), 12 months (89.7), 24 months (93.3), and 36 months (92.9). EPIC score decline from baseline was significant at end-of-treatment (p = 0.04) and 12 months post-treatment (p < 0.01). However, within 24 months, patient QOL demonstrated a return to pre-RT levels (p = 0.99).
Extreme hypofractionation was associated with a 4.58 point decrease in total EPIC-Bowel scores (p < 0.01) when compared to conventional fractionation, while hypofractionation was not associated with a significant decline (-1.42 points, p = 0.07). Both extreme hypofractionation (-4.06 points, p < 0.01) and hypofractionation (-2.47 points, p < 0.01) were significantly associated with decline in bowel function compared to conventional fractionation. Extreme hypofractionation was significantly associated with a decrease in bother scores (-5.12 points, p < 0.01), while hypofractionation was not (-0.40 points, p = 0.66).
Rectal dose affected QOL with the strongest DVH signals noted for BED D25 (Gy) with an optimal cut point of ≥23%. This parameter was significant after controlling for age, body mass index (BMI), race, Eastern Cooperative Oncology Group (ECOG) performance status ≥1, Gleason score, clinical T stage, androgen deprivation therapy (ADT) use, and fractionation schedule. For overall EPIC-Bowel scores, the dose of BED D25 (Gy) ≥23% was associated with an average decrease of 2.73 points compared to those <23% (p < 0.01). The effects of radiotherapy on bowel were subdivided into the domains of function and bother. A dose of BED D25 (Gy) ≥23% did not significantly affect bowel function (-1.44 points, p = 0.13). However, reported bother was significantly worse (p < 0.01) with a score difference of 4.06 points (
In a single, large prospective registry (n = 243), we determined BED to be an independent predictor for bowel-related QOL. Overall, EPIC-Bowel scores were significantly affected by BED D25 (Gy) ≥23% (p < 0.01). On multivariate modeling, this parameter was significantly associated with a decline in QOL scores measuring bother (p < 0.01, 4.06 points different) as opposed to function.
The MID for the EPIC-Bowel domain has been established as 4–6 points [
Potentially, these results can have different applications as we continue modifying radiation dose fractionations for the treatment of prostate cancer. Through the application of BED, we can minimize the risk of patient-reported toxicity regardless of dose fractionation, and compare different plans treated to different dose fractionation schemes. Since the toxicity is related to the biological effect, different doses with a similar biological effectiveness theoretically should impact QOL similarly.
We found extreme hypofractionation to be associated with a statistically and clinically significant decline in overall EPIC-Bowel scores, as well as individual function and bother scores, when compared to conventional fractionation (p < 0.01). Hypofractionation was not clinically significantly associated with a decrease in EPIC-Bowel scores—it was only found to be statistically significant for decrease in bowel function (p < 0.01) compared to conventional fractionation. These findings deserve further study into the effects of the separate fractionation schemes on QOL.
In our prior analysis, we observed a significant decline of the EPIC-Bowel domain associated with BED V51 (Gy) >14.3% (p = 0.01) and EQD2Gy V22 (Gy) >16.4% (p < 0.003) [
While the function subscale assessed topics such as bowel urgency, stool quality, and abdominal cramping, the bother subscale assessed how significantly these problems were perceived by patients. The differences in the scale suggest that patients have bother-related to radiation changes, but function was not affected. Thus, patients reported similar stool quality, but perception of the radiation effect on the change was larger than the perceived function. This can be interpreted in multiple ways: that patients can perceive differences in their stool quality for example, even though function is not affected, suggesting higher sensitivity to bother than a functional scale. Alternatively, the volume of the rectum that has developed radiation proctitis is relatively small. While the organ maintains function, but the small volume of rectum with proctitis can produce changes in bother in different subdomains. These findings may provide a more specific understanding of rectal toxicities associated with RT, guiding patient counseling.
Previous studies have supported the separate reporting of function and bother because treatment planning and symptom management may depend on a patients’ perceived experience [
One limitation of the present study is the difficulty in administration of a 50-item questionnaire. Although the EPIC-50 was used in order to retain granularity in the data collection, this poses certain challenges related to survey fatigue in patients [
In summary, this study demonstrates that BED can be used as an independent predictor for bowel QOL across conventional fractionation, hypofractionation and extreme hypofractionation schemes. We specifically determined BED D25 (Gy) ≥23% to be a statistically and clinically significant parameter for predicting decline in perceived bowel bother QOL. Therefore, BED can be a useful measure in prospective clinical trials to minimize symptom burden for patients undergoing PBT for prostate cancer, even when utilizing different dose fractionations.
No potential conflict of interest relevant to this article was reported.
EPIC-Bowel bother subdomain scores and survey samplings over time. EPIC, Expanded Prostate Cancer Index Composite; BED, biologically effective dose; EOT, end-of-treatment.
Patient and tumor characteristics (n = 243)
Characteristic | Value |
---|---|
Age (yr) | 71 (52–91) |
Race | |
White | 227 (93.4) |
Other | 16 (6.6) |
ECOG performance status | |
0 | 198 (81.5) |
1 | 44 (18.1) |
2 | 1 (0.4) |
1 or 2 | 45 (18.5) |
Pre-RT PSA (ng/ml) | 6.140 (0.3–1289) |
<10 | 185 (76.1) |
10–20 | 44 (18.1) |
>20 | 14 (5.8) |
T stage | |
T1-T2a | 188 (77.4) |
T2b-T2c | 32 (13.2) |
T3-T4 | 22 (9.1) |
Gleason score, total | |
6 (group 1) | 35 (14.4) |
7 (group 2 or 3) | 146 (60) |
3+4 (group 2) | 91 (37.4) |
4+3 (group 3) | 55 (22.6) |
8 (group 4) | 36 (14.8) |
9–10 (group 5) | 26 (10.7) |
Biopsy cores taken | 13 (2–34) |
Biopsy cores positive | 5 (1–25) |
MRI | |
Yes | 230 (94.7) |
No | 13 (5.3) |
MRI results | |
Extraprostatic extension | 27 (11.1) |
Seminal vesicle invasion | 5 (2.1) |
Androgen deprivation therapy | |
Yes | 155 (63.8) |
No | 88 (36.2) |
Values are presented as median (range) or number (%).
ECOG, Eastern Cooperative Oncology Group; RT, radiotherapy; PSA, prostate-specific antigen; MRI, magnetic resonance imaging.
Dose fractionation with BED and EQD2Gy transformations
Prostate |
Rectum |
Total number (%) | |||
---|---|---|---|---|---|
BED (α/β = 1.5) | EQD2Gy | BED (α/β = 3) | EQD2Gy | ||
Dose fractionation (SBRT) | |||||
38 Gy/5 fx | 230.5 | 98.8 | 134.3 | 80.6 | 42 (17.3) |
Hypofractionation | |||||
60 Gy/20 fx | 180 | 77.1 | 120 | 72 | 9 (3.7) |
67.5 Gy/25 fx | 189 | 81 | 128.3 | 77.0 | 26 (10.7) |
70 Gy/28 fx | 180 | 77.1 | 128.3 | 77 | 49 (20.2) |
Conventional fractionation | |||||
75.6 Gy/42 fx | 166.3 | 71.3 | 121.0 | 72.6 | 1 (0.4) |
77.4 Gy/43 fx | 170.3 | 73 | 123.8 | 74.3 | 8 (3.3) |
78 Gy/39 fx | 182 | 78 | 130 | 78 | 2 (0.8) |
79.2 Gy/44 fx | 174.2 | 74.7 | 126.7 | 76.0 | 106 (43.6) |
BED, biologically effective dose; EQD2Gy, equivalent dose in 2 Gy fractions; SBRT, stereotactic body radiation therapy.
Univariate analysis of DVH parameters used in selecting BED D25 Gy (p = 0.027) as the optimal predictor for differences in EPIC-Bowel, to be evaluated through subsequent multivariate analysis
BED |
EQD2Gy |
Total dose |
||||
---|---|---|---|---|---|---|
Median | p-value | Median | p-value | Median | p-value | |
Dmean | 12.050 | NS | 7.230 | NS | 8.080 | NS |
D0 | 132.090 | NS | 79.250 | NS | 72.070 | 0.0008 |
D5 | 87.040 | NS | 52.220 | NS | 53.030 | NS |
D10 | 43.410 | NS | 26.050 | NS | 31.560 | NS |
D15 | 20.090 | NS | 12.050 | NS | 16.510 | NS |
D20 | 9.770 | 0.0338 | 5.860 | 0.0338 | 8.790 | NS |
D25 | 4.990 | 0.0270 | 2.990 | 0.0270 | 4.630 | 0.0402 |
D30 | 2.790 | 0.0349 | 1.680 | 0.0349 | 2.690 | 0.0352 |
D35 | 1.730 | NS | 1.040 | NS | 1.700 | 0.0490 |
D40 | 1.250 | NS | 0.750 | NS | 1.230 | NS |
D50 | 0.720 | NS | 0.430 | NS | 0.710 | NS |
D60 | 0.400 | NS | 0.240 | NS | 0.400 | NS |
D70 | 0.202 | NS | 0.121 | NS | 0.200 | NS |
D80 | 0.070 | NS | 0.040 | NS | 0.070 | NS |
D90 | 0.007 | NS | 0.004 | NS | 0.007 | NS |
D95 | 0.001 | 0.0013 | 0.001 | 0.0013 | 0.001 | 0.0013 |
D100 | 0 | 0.0004 | 0 | 0.0004 | 0 | 0.0004 |
V10 | 19.800 | NS | 16.410 | NS | 19.030 | NS |
V20 | 15.040 | NS | 11.930 | NS | 13.470 | NS |
V30 | 12.480 | NS | 8.910 | NS | 10.420 | NS |
V40 | 10.410 | NS | 7.210 | NS | 7.810 | NS |
V50 | 8.910 | NS | 5.380 | NS | 5.720 | NS |
V60 | 7.810 | NS | 3.920 | NS | 3.360 | NS |
V65 | 7.400 | NS | 3.040 | NS | 2.390 | 0.0566 |
V70 | 6.770 | NS | 2.070 | NS | 0.700 | 0.0093 |
V80 | 5.740 | NS | 0 | NS | - | - |
V90 | 4.740 | NS | - | - | - | - |
V100 | 3.920 | NS | - | - | - | - |
V110 | 2.790 | NS | - | - | - | - |
V120 | 1.640 | NS | - | - | - | - |
V125 | 1.010 | NS | - | - | - | - |
DVH, dose-volume histogram; BED, biologically effective dose; EQD2Gy, equivalent dose in 2 Gy fractions; EPIC, Expanded Prostate Cancer Index Composite; NS, not significant.